Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Commensal Cross-Reactive T & B Cells Trigger Autoimmunity

Kurt Ullman  |  October 26, 2020

Antigens from the microbiota are constantly identified by the immune system, generating a pool of memory T cells and immunoglobulin G (IgG) memory B cells. These immune cells can then cross-react with antigens from the host, which can contribute to the pathogenesis of autoimmune disease. A study in Cell Host & Microbe looks at this interaction in patients with antiphospholipid syndrome (APS).1

“APS is understudied and undertreated,” says Martin A. Kriegel, MD, PhD, senior author and adjunct professor of immunobiology at Yale School of Medicine, New Haven, Conn. “In APS, the role of the microbiome hasn’t been considered in depth. Given the sheer number of microbes we have, there are quite a few likely to stimulate both T and B cells, which are major drivers of autoimmunity.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Roseburia Intestinalis Exhibits Protein Resembling APS Autoantigen
The researchers searched for a CD4+ Tv cell epitope and the major B cell epitope in the APS autoantigen β2-glycoprotein I (β2GPI) to bacterial proteins in non-redundant protein databases. Candidate sequences were used to identify human commensal gut bacteria with homology to both well-defined autoepitopes. They identified Roseburia intestinalis (R. intestinalis) as a common bacterium that expresses proteins that closely resemble these two epitopes.

Patients with APS who had evidence of immune recognition of R. intestinalis also demonstrated subclinical signs of intestinal inflammation. Human β2GPI-autoreactive lymphocytes and autoantibodies from APS patients cross-reacted with homologous areas expressed by R. intestinalis. Specifically, autoantigen-reactive CD4+ memory T cell clones and an APS-derived monoclonal antibody cross-reacted with epitopes from R. intestinalis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Core-sequence-dependent anti-R. intestinalis IgG titers were significantly elevated in APS patients, and correlated with anti-β2GPI IgG autoantibodies. Additionally, the bacterium was identified as a chronic driver of β2GPI autoreactivity in a murine model, demonstrating T and B cell cross reactivity in vivo with progression in APS-prone mice.

Dr. Kriegel

Cross-Reactive Triggers: A Potential Risk Factor
“One of the interesting things coming out of our research is that a bug that is beneficial in disease A, can be really bad in disease B,” says Dr. Kriegel. “This [finding] is especially true in autoimmune diseases in which the immune system overshoots in different ways depending on the disease. In APS, based on these cross-reactive triggers in R. intestinalis, the presence of R. intestinalis can be a potential risk factor for autoimmune disease, but may have metabolic benefits for gut inflammation. The risk of one autoimmune disease may be related to different aspects of the same bacterium that mitigates another autoimmune disease.”

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)Hughes SyndromeMicrobiomemicrobiota

Related Articles

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

    February 1, 2014

    With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch

    Studies Find More Evidence the Microbiome Affects Autoimmune Disease

    August 17, 2018

    Evidence is accumulating that the microbiome may be an important part of the pathogenesis of many autoimmune diseases. Two recently published articles report on how translocation of the gut bacterium Enterococcus gallinarum drives autoimmunity in mice and humans, and on the role of other commensal bacteria in triggering immune responses—specifically to the autoantigen Ro60, which…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences